2024 ICD-10-CM Diagnosis Code T46.6X5S
Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
- ICD-10-CM Code:
- T46.6X5S
- ICD-10 Code for:
- Advrs effect of antihyperlip and antiarterio drugs, sequela
- Is Billable?
- Yes - Valid for Submission
- Chronic Condition Indicator: [1]
- Not chronic
- Code Navigator:
- Code Information
- Approximate Synonyms
- Clinical Classification
- Clinical Information
- Coding Guidelines
- Tabular List of Diseases and Injuries
- Code Edits
- Diagnostic Related Groups Mapping
- Present on Admission (POA)
- Convert to ICD-9 Code
- Table of Drugs and Chemicals
- Patient Education
- Other Codes Used Similar Conditions
- Code History
T46.6X5S is a billable diagnosis code used to specify a medical diagnosis of adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.
This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
T46.6X5S is a sequela code, includes a 7th character and should be used for complications that arise as a direct result of a condition like adverse effect of antihyperlipidemic and antiarteriosclerotic drugs. According to ICD-10-CM Guidelines a "sequela" code should be used for chronic or residual conditions that are complications of an initial acute disease, illness or injury. The most common sequela is pain. Usually, two diagnosis codes are needed when reporting sequela. The first code describes the nature of the sequela while the second code describes the sequela or late effect.
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Acipimox adverse reaction
- Adverse reaction caused by atorvastatin
- Adverse reaction caused by cerivastatin
- Adverse reaction caused by fluvastatin
- Adverse reaction caused by lovastatin
- Adverse reaction caused by pitavastatin
- Adverse reaction caused by pravastatin
- Adverse reaction caused by rosuvastatin
- Adverse reaction caused by simvastatin
- Anion exchange resins adverse reaction
- Bezafibrate adverse reaction
- Cholestyramine adverse reaction
- Ciprofibrate adverse reaction
- Clofibrate adverse reaction
- Colestipol adverse reaction
- Complication of preventive medicine procedure
- Fenofibrate adverse reaction
- Fibric acid and/or fibric acid derivative adverse reaction
- Gemfibrozil adverse reaction
- Guar gum adverse reaction
- HMG COA reductase inhibitor adverse reaction
- Ion exchange resin adverse reaction
- Ion exchange resin adverse reaction
- Lipid-lowering drug adverse reaction
- Myalgia caused by statin
- Probucol adverse reaction
- Rhabdomyolysis due to statin
Clinical Classification
Clinical Category is Poisoning/toxic effect/adverse effects/underdosing, sequela
- CCSR Category Code: INJ075
- Inpatient Default CCSR: X - Not applicable.
- Outpatient Default CCSR: Y - Yes, default outpatient assignment for principal diagnosis or first-listed diagnosis.
Clinical Information
Bezafibrate
an antilipemic agent that lowers cholesterol and triglycerides. it decreases low density lipoproteins and increases high density lipoproteins.Clofibrate
a fibric acid derivative used in the treatment of hyperlipoproteinemia type iii and severe hypertriglyceridemia. (from martindale, the extra pharmacopoeia, 30th ed, p986)Colestipol
highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. it may also may reduce triglyceride levels.Fenofibrate
an antilipemic agent which reduces both cholesterol and triglycerides in the blood.Gemfibrozil
a lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.Halofenate
an antihyperlipoproteinemic agent and uricosuric agent.Linoleic Acid
a doubly unsaturated fatty acid, occurring widely in plant glycosides. it is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (from stedman, 26th ed)Linoleic Acids
eighteen-carbon essential fatty acids that contain two double bonds.Linoleic Acids, Conjugated
a collective term for a group of around nine geometric and positional isomers of linoleic acid in which the trans/cis double bonds are conjugated, where double bonds alternate with single bonds.Linoleoyl-CoA Desaturase
an enzyme that catalyzes the syn-dehydrogenation of linoleol-coa gamma-linolenoyl-coa. it was formerly characterized as ec 1.14.99.25.Lovastatin
a fungal metabolite isolated from cultures of aspergillus terreus. the compound is a potent anticholesteremic agent. it inhibits 3-hydroxy-3-methylglutaryl coenzyme a reductase (hydroxymethylglutaryl coa reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. it also stimulates the production of low-density lipoprotein receptors in the liver.Oleic Acid
an unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. it is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (stedman, 26th ed)Oleic Acids
a group of fatty acids that contain 18 carbon atoms and a double bond at the omega 9 carbon.Ricinoleic Acids
eighteen carbon fatty acids that comprise the great majority of castor oil, which is from the seed of ricinus.Pravastatin
an antilipemic fungal metabolite isolated from cultures of nocardia autotrophica. it acts as a competitive inhibitor of hmg coa reductase (hydroxymethylglutaryl coa reductases).Probucol
a drug used to lower ldl and hdl cholesterol yet has little effect on serum-triglyceride or vldl cholesterol. (from martindale, the extra pharmacopoeia, 30th ed, p993).Safflower Oil
an oily liquid extracted from the seeds of the safflower, carthamus tinctorius. it is used as a dietary supplement in the management of hypercholesterolemia. it is used also in cooking, as a salad oil, and as a vehicle for medicines, paints, varnishes, etc. (dorland, 28th ed & random house unabridged dictionary, 2d ed)Simvastatin
a derivative of lovastatin and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase (hydroxymethylglutaryl coa reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. it may also interfere with steroid hormone production. due to the induction of hepatic ldl receptors, it increases breakdown of ldl cholesterol.Sitosterols
a family of sterols commonly found in plants and plant oils. alpha-, beta-, and gamma-isomers have been characterized.Triparanol
antilipemic agent with high ophthalmic toxicity. according to merck index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.
Coding Guidelines
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46). Use the following options for the aplicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:
- Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.
Present on Admission (POA)
T46.6X5S is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.
CMS POA Indicator Options and Definitions
POA Indicator | Reason for Code | CMS will pay the CC/MCC DRG? |
---|---|---|
Y | Diagnosis was present at time of inpatient admission. | YES |
N | Diagnosis was not present at time of inpatient admission. | NO |
U | Documentation insufficient to determine if the condition was present at the time of inpatient admission. | NO |
W | Clinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission. | YES |
1 | Unreported/Not used - Exempt from POA reporting. | NO |
Convert T46.6X5S to ICD-9-CM
- ICD-9-CM Code: 909.5 - Lte efct advrs efct drug
Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment. - ICD-9-CM Code: E942.2 - Adv eff antilipemics
Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.
Table of Drugs and Chemicals
The parent code T46.6X5 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.
According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.
Patient Education
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
What is a drug interaction?
A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:
- Two drugs, such as aspirin and blood thinners
- Drugs and food, such as statins and grapefruit
- Drugs and supplements, such as gingko and blood thinners
- Drugs and medical conditions, such as aspirin and peptic ulcers
Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.
What are side effects?
Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.
What are drug allergies?
Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.
How can I stay safe when taking medicines?
When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.
[Learn More in MedlinePlus]
Code History
- FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
- FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
- FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.